<DOC>
	<DOCNO>NCT02979015</DOCNO>
	<brief_summary>Primary Objective : To assess safety tolerability ascend single SC dose alirocumab Chinese healthy subject . Secondary Objectives : - To assess pharmacokinetic profile single SC dose alirocumab . - To assess pharmacodynamic effect single SC dose alirocumab low-density lipoprotein cholesterol ( LDL-C ) lipid parameter . - To assess immunogenicity single SC dose alirocumab .</brief_summary>
	<brief_title>A Study Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Subcutaneous ( SC ) Administered Alirocumab Healthy Chinese Subjects</brief_title>
	<detailed_description>Ascending dose design include 3 dose level . Tolerance data least 14 day post dose least 6 subject previous cohort review proceed next dose . Total duration study per subject approximately 15 week ( include screen period ) .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Healthy male female subject . Aged 18 45 year old . Lowdensity lipoprotein cholesterol &gt; 100 mg/dL ( 2.59 mmol/L ) . Exclusion criterion : Subjects history presence clinically relevant illness . Serum triglycerides &gt; 200 mg/dL ( 2.26 mmol/L ) measure least 10 hour fasting . Use medication nutraceutical order alter serum lipid within 4 week prior screen , include limited statin , ezetimibe , fibrates , niacin , bile acid resin . Use probucol within 8 week prior screen . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>